Chemistry:Ivonescimab
Ivonescimab is a humanized bispecific monoclonal antibody currently being trialed for use against non-small-cell lung cancer. Developed by Akeso Biopharma, it has been approved in China for the treatment of epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous NSCLC in patients who have progressed past tyrosine kinase inhibitor therapy,[1] and is undergoing clinical trials elsewhere.
Mechanism of action
Ivonescimab prevents tumor proliferation and angiogenesis by inhibiting programmed cell death protein 1 and vascular endothelial growth factor A, respectively.[2]
Research
Ivonescimab so far has only completed trials in Chinese patients,[3] and is currently undergoing phase III trials in the United States for the treatment of non-squamous non-small-cell lung cancer and advanced NSCLC.[4]
Society and culture
The initial success of ivonescimab in trials is compared to already-approved drugs such as Merck & Co.'s Keytruda (pembrolizumab); its success has been described as important for the pharmaceutical industry in China.[5]
See also
References
- ↑ "国家药监局批准依沃西单抗注射液上市" (in zh). 24 May 2024. https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20240524110617125.html.
- ↑ "1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects". Journal for Immunotherapy of Cancer 11: A1316–A1317. November 2023. doi:10.1136/jitc-2023-SITC2023.1194. https://jitc.bmj.com/content/11/Suppl_1/A1316.
- ↑ "HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC". 25 September 2024. https://ascopost.com/issues/september-25-2024/iaslc-ivonescimab-vs-pembrolizumab-as-first-line-treatment-in-nsclc/.
- ↑ "Ivonescimab: First Approval". Drugs 84 (9): 1135–1142. September 2024. doi:10.1007/s40265-024-02073-w. PMID 39073550.
- ↑ "A little-known Chinese company made a drug that beat the world's biggest-selling medicine". 25 February 2025. https://www.cnn.com/2025/02/25/business/china-biotech-global-disruption-intl-hnk/index.html.
External links
- Clinical trial number NCT05499390 for "AK112 in Advanced Non-Small Cell Lung Cancer" at ClinicalTrials.gov
- Clinical trial number NCT05184712 for "Phase 3 Clinical Study of AK112 for NSCLC Patients" at ClinicalTrials.gov
 |  |
